Honasa buys 58% of Fluence Pharma for Rs 135 cr, launches Honasa Health for nutraceuticals
Mamaearth parent Honasa Consumer is moving deeper into health and wellness, acquiring a controlling 58% stake in Fluence Pharma at a Rs 135 crore enterprise value with a runway to absorb the remaining 42% over 5-7 years. It has also incorporated a new B2C subsidiary, Honasa Health, to build a nutraceuticals play.
What happened
Honasa Consumer (Mamaearth parent) approved acquisition of 58% in Fluence Pharma for Rs 135 crore EV, with plans to absorb the remaining 42% over 5-7 years, and
Key facts
- 58% stake
- Rs 135 crore EV
- 42% remaining over 5-7 years
Why this matters
Phased majority deals with 5-7 year full-buyout runways are emerging as the preferred FMCG-to-wellness M&A template, letting acquirers validate integration before committing full equity.